Peer-reviewed veterinary case report
Masitinib treatment improves itching and skin lesions in dogs
By Daigle, Jenise et al.·Published in Veterinary research communications·2010·Austin Veterinary Dermatology, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Masitinib for the treatment of canine atopic dermatitis: a pilot study.
- Species:
- dog
Plain-English summary
Eleven dogs with itchy skin and rashes due to canine atopic dermatitis (CAD) were treated with a medication called masitinib for 28 days. The treatment led to a significant improvement in their skin condition, with many dogs showing a reduction in itchiness and the size of their lesions. Most dogs experienced at least a 33% improvement, and there were no serious side effects, although some had mild reactions. This suggests that masitinib could be a promising option for managing CAD, and further studies are encouraged.
People also search for: dog itchy skin treatment · masitinib for dog allergies · canine atopic dermatitis medication
Abstract
There is an on-going need to identify medications suitable for the long-term treatment of canine atopic dermatitis (CAD). Masitinib mesilate is a potent and selective tyrosine kinase inhibitor of the c-KIT receptor. A strong relationship exists between the SCF/c-KIT pathway and pathogenesis of CAD, suggesting that masitinib may potentially fulfil the above role. This study reports on an uncontrolled pilot study of masitinib in CAD. Masitinib was administered orally to 11 dogs at a mean dose of 11.0 +/- 1.83 mg/kg/day (free base) for 28 days. Treatment response was assessed by evolution of clinical appearance according to a modified version of the Canine Atopic Dermatitis Extent and Severity Index (mCADESI), pruritus scale and surface area of lesions. Masitinib improved CAD with a mean reduction in mCADESI of 50.7 +/- 29.8% (95% C.I. = 29.4-72.0; p = 0.0004) at day 28 relative to baseline, with 8/10, 8/10 and 4/10 dogs showing improvement of >or=33%, >or=40% and >or=50%, respectively. Improvement was further evidenced by a decrease in pruritus score and the surface area of lesions. No serious or severe adverse events occurred during this trial, although 6/11 dogs presented with mild to moderate treatment related adverse events. There is sufficient compelling evidence to warrant further investigation.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/20033487/